Nisa Investment Advisors LLC Boosts Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Nisa Investment Advisors LLC lifted its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 19.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,517 shares of the biopharmaceutical company’s stock after purchasing an additional 1,076 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Dynavax Technologies were worth $83,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Assenagon Asset Management S.A. acquired a new position in Dynavax Technologies in the 3rd quarter worth approximately $8,291,000. Entropy Technologies LP acquired a new stake in shares of Dynavax Technologies in the third quarter worth $462,000. Nordea Investment Management AB raised its holdings in shares of Dynavax Technologies by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 232,690 shares during the last quarter. Bank of Montreal Can lifted its position in Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after purchasing an additional 82,449 shares during the period. Finally, Millennium Management LLC purchased a new stake in Dynavax Technologies in the second quarter valued at $17,615,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Trading Up 0.2 %

Shares of Dynavax Technologies stock opened at $13.01 on Friday. The firm has a 50-day simple moving average of $12.75 and a two-hundred day simple moving average of $11.78. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $13.89. The company has a market cap of $1.71 billion, a P/E ratio of 100.08 and a beta of 1.34.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. The company had revenue of $80.63 million during the quarter, compared to analysts’ expectations of $83.64 million. During the same quarter in the prior year, the firm posted $0.10 EPS. As a group, equities analysts predict that Dynavax Technologies Co. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DVAX. HC Wainwright lifted their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, January 14th. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.